Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on LATAM Daily Brief.
Press releases published on April 1, 2025
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire
·
April 1, 2025
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster …
Stallion Uranium Announces C$1.2 Million Private Placement
GlobeNewswire
·
April 1, 2025
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) -- Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) is pleased to …
What’s on in Puerto Vallarta this Spring and Summer
GlobeNewswire
·
April 1, 2025
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Puerto Vallarta, Mexico’s oceanside resort city tucked between the Sierra Madre Mountains and Banderas Bay, unveils a dynamic lineup of spring and summer events. As the months heat up, this world-class …
Bitget Wallet Launches First LSD Earn Zone, Introducing Flexible Onchain Yield
GlobeNewswire
·
April 1, 2025
SAN SALVADOR, El Salvador, April 01, 2025 (GLOBE NEWSWIRE) -- Bitget Wallet, a leading Web3 non-custodial wallet, has launched the industry's first LSD Earn Zone, offering users a new way to earn onchain yields while keeping their crypto assets liquid. …
GCC Announces Q1 2025 Conference Call Details
GlobeNewswire
·
April 1, 2025
CHIHUAHUA, Mexico, April 01, 2025 (GLOBE NEWSWIRE) -- GCC, S.A.B. de C.V. (BMV: GCC*), a leading producer of cement and concrete in the United States and Mexico, will host a conference call to review its first quarter 2025 earnings results on Wednesday, …
GRI Bio Announces Pricing of $5.0 Million Public Offering
GlobeNewswire
·
April 1, 2025
LA JOLLA, CA, April 01, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and …
YPF SA reports
GlobeNewswire
·
April 1, 2025
BUENOS AIRES, Argentina, April 01, 2025 (GLOBE NEWSWIRE) -- YPF SA announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2024, with the US Securities and Exchange Commission, including audited financial …
Personal Injury Attorney Michael Colbach Celebrates 20th Year as Title Sponsor Of The Bicycle Attorney Cycling Team
EIN Presswire
·
April 1, 2025
A collaboration and ongoing commitment to making a positive impact through cycling. PORTLAND, OR, UNITED STATES, March 31, 2025 /EINPresswire.com/ -- Michael Colbach is deeply rooted in Oregon, growing up in West Linn and graduating from Lewis …
Endeavour Silver Increases Previously Announced Bought Deal Financing to US$45 Million
GlobeNewswire
·
April 1, 2025
The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ All dollar amounts are stated in United States (U.S.) Dollars unless otherwise noted. VANCOUVER, British Columbia, April 01, …
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
GlobeNewswire
·
April 1, 2025
– FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Expect to initiate both trials in Q2 2025 – SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- …
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire
·
April 1, 2025
The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data reviewed Interim results demonstrate GRI-0621 to be safe and well-tolerated in the first 12 patients evaluated …
ENTOUCH Unveils Revolutionary ENTelligent Insights to Transform Energy Management
EIN Presswire
·
April 1, 2025
Continued Machine Learning Expansion Leads the Energy Management Offering RICHARDSON, TX, UNITED STATES, March 31, 2025 /EINPresswire.com/ -- ENTOUCH, a leader in energy management and smart building technology for multisite operators, proudly announces …
"Me Enamoré" lleva a La Original Banda El Limón de Salvador Lizárraga al #1 en Varios Charts
EIN Presswire
·
April 1, 2025
"Me Enamoré" También Arrasa en Monitor Latino: #1 en Regional Mexicano y General LOS ANGELES, CA, UNITED STATES, March 31, 2025 /EINPresswire.com/ -- ICCF-- La Original Banda El Limón de Salvador Lizárraga sigue imparable con su más reciente éxito, "Me …
Clene to Present at the Jones Healthcare and Technology Innovation Conference
GlobeNewswire
·
April 1, 2025
SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the …
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
GlobeNewswire
·
April 1, 2025
The clinical trial is designed to evaluate the safety, tolerability and efficacy of Clearmind’s innovative, psychedelic-derived, MEAI-based compound in individuals with alcohol addiction Vancouver, Canada, April 01, 2025 (GLOBE NEWSWIRE) -- Clearmind …
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
GlobeNewswire
·
April 1, 2025
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of …
Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis
GlobeNewswire
·
April 1, 2025
Topline data from the single- and multiple-ascending dose studies confirmed safety and favorable tolerability profile of AP02 at all dose levels Full safety, tolerability, and pharmacokinetics data to be presented at the American Thoracic Society 2025 …
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme
GlobeNewswire
·
April 1, 2025
CARLSBAD, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today they have entered a non-binding Memorandum of Understanding (MOU) to acquire Marizyme (OTC: MRZM). Qualigen and Marizyme have …
Context Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
April 1, 2025
PHILADELPHIA, April 01, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its …
Endeavour Silver Announces Expansion into Peru with Acquisition of Minera Kolpa, Copper Stream and Bought Deal Financing
GlobeNewswire
·
April 1, 2025
The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ All dollar amounts are stated in United States (U.S.) Dollars unless otherwise noted. VANCOUVER, British Columbia, April 01, …